Details of the Drug

General Information of Drug (ID: DMS60RB)

Drug Name

Levofloxacin

Synonyms

Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

361.4

Topological Polar Surface Area (xlogp)

-0.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 11.5 +/- 4.0 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-2 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: The bioavailability of drug is 99% [2]
Clearance: The renal clearance of drug is 5.76-8.52 L/h [4]
Elimination: Following the administration of a single oral dose of levofloxacin, approximately 87% was eliminated unchanged in the urine within 48 hours and less than 4% was eliminated in the feces within 72 hours [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 8 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 29.6483 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.13% [6]
Vd: The volume of distribution (Vd) of drug is 89-112 L [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.75 mg/mL [3]

Chemical Identifiers

Formula: C18H20FN3O4
IUPAC Name: (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Canonical SMILES: C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
InChI: InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
InChIKey: GSDSWSVVBLHKDQ-JTQLQIEISA-N

Cross-matching ID

PubChem CID: 149096
ChEBI ID: CHEBI:63598
CAS Number: 100986-85-4
DrugBank ID: DB01137
TTD ID: D02RSN
VARIDT ID: DR00046
INTEDE ID: DR2456
ACDINA ID: D00361

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Modulator	[7]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Modulator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Beta-lactamase (blaB)_{Main DME}	DEP0IWS	A0A378EHS6_KLEPR	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Levofloxacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[33]
-----------

Coadministration of a Drug Treating the Disease Different from Levofloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Levofloxacin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[34]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[35]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[33]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Idarubicin.	Acute myeloid leukaemia [2A60]	[33]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[36]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[37]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Oliceridine.	Acute pain [MG31]	[33]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Ivabradine.	Angina pectoris [BA40]	[36]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Bepridil.	Angina pectoris [BA40]	[38]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Dronedarone.	Angina pectoris [BA40]	[39]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[40]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Cilostazol.	Arterial occlusive disease [BD40]	[33]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Posaconazole.	Aspergillosis [1F20]	[33]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Levalbuterol.	Asthma [CA23]	[41]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Pirbuterol.	Asthma [CA23]	[42]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[36]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[33]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Retigabine.	Behcet disease [4A62]	[33]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Levofloxacin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[43]
Lomustine	DMMWSUL	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[44]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[39]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[33]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[44]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Bosutinib.	Breast cancer [2C60-2C6Y]	[36]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[42]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[41]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[42]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[42]
Mestranol	DMG3F94	Moderate	Decreased absorption of Levofloxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[45]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Halothane.	Corneal disease [9A76-9A78]	[33]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[39]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Probucol.	Coronary atherosclerosis [BA80]	[33]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Pasireotide.	Cushing syndrome [5A70]	[39]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Osilodrostat.	Cushing syndrome [5A70]	[36]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Escitalopram.	Depression [6A70-6A7Z]	[39]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Clomipramine.	Depression [6A70-6A7Z]	[33]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Doxepin.	Depression [6A70-6A7Z]	[33]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[39]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Deutetrabenazine.	Dystonic disorder [8A02]	[46]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Ingrezza.	Dystonic disorder [8A02]	[47]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Levofloxacin and Cannabidiol.	Epileptic encephalopathy [8A62]	[36]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Solifenacin.	Functional bladder disorder [GC50]	[33]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[33]
Procarbazine	DMIK367	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[44]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Levofloxacin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[48]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Levofloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[51]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Levofloxacin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[52]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Levofloxacin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[39]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Levofloxacin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[53]
Iron	DMAP8MV	Moderate	Decreased absorption of Levofloxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[54]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Levofloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[39]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[39]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Crizotinib.	Lung cancer [2C25]	[55]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Ceritinib.	Lung cancer [2C25]	[39]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[44]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Osimertinib.	Lung cancer [2C25]	[56]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Lumefantrine.	Malaria [1F40-1F45]	[34]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Halofantrine.	Malaria [1F40-1F45]	[57]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[58]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[36]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Levofloxacin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[59]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Levofloxacin and Idelalisib.	Mature B-cell leukaemia [2A82]	[60]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[61]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Vemurafenib.	Melanoma [2C30]	[39]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and LGX818.	Melanoma [2C30]	[62]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Levofloxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[39]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Panobinostat.	Multiple myeloma [2A83]	[63]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Siponimod.	Multiple sclerosis [8A40]	[34]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Fingolimod.	Multiple sclerosis [8A40]	[39]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Levofloxacin and Ozanimod.	Multiple sclerosis [8A40]	[64]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Levofloxacin and Deflazacort.	Muscular dystrophy [8C70]	[65]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Romidepsin.	Mycosis fungoides [2B01]	[33]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[39]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[33]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Levofloxacin and Bupropion.	Nicotine use disorder [6C4A]	[66]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[34]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[36]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Lofexidine.	Opioid use disorder [6C43]	[39]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Rucaparib.	Ovarian cancer [2C73]	[33]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[33]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Pimavanserin.	Parkinsonism [8A00]	[67]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[68]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Lefamulin.	Pneumonia [CA40]	[69]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Levofloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[70]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Degarelix.	Prostate cancer [2C82]	[36]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and ABIRATERONE.	Prostate cancer [2C82]	[36]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Enzalutamide.	Prostate cancer [2C82]	[36]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Relugolix.	Prostate cancer [2C82]	[36]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[33]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Levofloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[70]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Levofloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[65]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Quetiapine.	Schizophrenia [6A20]	[39]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Aripiprazole.	Schizophrenia [6A20]	[34]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Iloperidone.	Schizophrenia [6A20]	[39]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Paliperidone.	Schizophrenia [6A20]	[33]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Amisulpride.	Schizophrenia [6A20]	[71]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Asenapine.	Schizophrenia [6A20]	[39]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[44]
Docetaxel	DMDI269	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[44]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Levofloxacin and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[36]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[44]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[39]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[39]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[36]
Taxol	DMUOT9V	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[44]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Pitolisant.	Somnolence [MG42]	[36]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[33]
Plicamycin	DM7C8YV	Minor	Decreased absorption of Levofloxacin due to intestinal mucosa variation caused by Plicamycin.	Testicular cancer [2C80]	[44]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Lenvatinib.	Thyroid cancer [2D10]	[33]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Levofloxacin and Cabozantinib.	Thyroid cancer [2D10]	[36]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[34]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[33]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Levofloxacin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[33]
-----------


⏷ Show the Full List of 117 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Levofloxacin 500 mg tablet	500 mg	Oral Tablet	Oral
Levofloxacin 250 mg tablet	250 mg	Oral Tablet	Oral
Levofloxacin 750 mg tablet	750 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
2	FDA Approved Drug Products: Levaquin (levofloxacin) oral tablets
3	BDDCS applied to over 900 drugs
4	The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997 Feb;32(2):101-19. doi: 10.2165/00003088-199732020-00002.
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
9	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
11	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
13	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
14	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
15	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
16	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
17	Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
18	Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
19	Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
20	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
21	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
22	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
23	Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
24	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
25	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
26	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
27	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
28	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
29	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
30	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
31	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
32	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
33	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
34	Cerner Multum, Inc. "Australian Product Information.".
35	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
36	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
38	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
39	Canadian Pharmacists Association.
40	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
41	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
42	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
43	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
44	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
45	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
46	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
47	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
48	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
49	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
50	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
51	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
52	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
53	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
54	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
55	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
56	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
58	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
59	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
60	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
61	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
62	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
64	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
65	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
66	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
67	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
68	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
69	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
70	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
71	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.